ライフサイエンスコーパス: clinical trial

1 Cerebral Hemorrhage II (ATACH-II) randomized clinical trial.

2 roximately 12 weeks, as part of a three-site clinical trial.

3 f Sedation Titration for Respiratory Failure clinical trial.

4 pective, randomized, multicenter, controlled clinical trial.

5 h patient samples in a matched system design clinical trial.

6 equence of this diet will now be tested in a clinical trial.

7 domized, controlled, multicenter, open-label clinical trial.

8 should only be advocated in the context of a clinical trial.

9 itutions, and the UKCCSG-SIOP-PNET3 European clinical trial.

10 ocally advanced NSCLC in a large prospective clinical trial.

11 trong rationale for a confirmatory phase III clinical trial.

12 d by NGMS in 4 samples from 2 persons in the clinical trial.

13 s been used in an outbreak setting outside a clinical trial.

14 pro-cognitive drug discovery and early-phase clinical trials.

15 are less rigorous than those for drug/device clinical trials.

16 e first to be evaluated as IDO inhibitors in clinical trials.

17 ic end points and response to therapy in AMD clinical trials.

18 ogression, which can confound the results of clinical trials.

19 eutic in preclinical studies and early-phase clinical trials.

20 uture work to move CNGB1-RP therapies toward clinical trials.

21 ndardized to maximize safety and efficacy in clinical trials.

22 y all human brain and behavioral research as clinical trials.

23 o improve outcomes were tested in randomised clinical trials.

24 an be used for risk stratification in future clinical trials.

25 ctrophotometric method and can be applied to clinical trials.

26 have led to their steady progression through clinical trials.

27 ute to heterogeneous therapeutic outcomes in clinical trials.

28 n natural history studies and interventional clinical trials.

29 tively homogeneous subgroups of subjects for clinical trials.

30 ostics, and applicability to next-generation clinical trials.

31 further mechanistic study and translation to clinical trials.

32 Children's Oncology Group B-cell ALL (B-ALL) clinical trials.

33 and niraparib-an anticancer agent in several clinical trials.

34 nd ERK are currently being targeted in human clinical trials.

35 and to determine intermediate endpoints for clinical trials.

36 lower rates of CVD and did not reduce CVD in clinical trials.

37 viral drugs that might be explored in future clinical trials.

38 ptors 1, 2, and 3, currently in phase II/III clinical trials.

39 ovel-agent combinations for further study in clinical trials.

40 ising new cancer drugs and later phase adult clinical trials.

41 patients with trigeminal neuralgia in future clinical trials.

42 actate monohydrate suitable for use in human clinical trials.

43 developed and are currently in use in human clinical trials.

44 rge field studies and outcome assessments in clinical trials.

45 erating reliable data in allergy multicenter clinical trials.

46 ine PDAC, suggesting this concept for future clinical trials.

47 estigated as health promoting foods in human clinical trials.

48 missions and mortality are often outcomes in clinical trials.

49 of schizophrenia patients, warranting larger clinical trials.

50 tch protein activity have already moved into clinical trials.

51 management and less participation of men in clinical trials.

52 s in clinical practice and for the design of clinical trials.

53 course with 3 compounds failing in phase III clinical trials.

54 al, but to date, no vaccines have made it to clinical trials.

55 nt implications for stratification of future clinical trials.

56 ated in subtype-specific or biomarker-driven clinical trials.

57 nsion (PAH) is hampered by lack of pediatric clinical trials.

58 -C) showed limited immunogenicity in phase I clinical trials.

59 o identify the optimal timing for future DHA clinical trials.

60 to highlight areas of importance for future clinical trials.

61 ls and prevent recurrent infections in human clinical trials.

62 as for selecting appropriate individuals for clinical trials.

63 tment can be established only via randomized clinical trials.

64 and several other compounds are in advanced clinical trials.

65 al population and exclude many patients from clinical trials.

66 assessed for response and are excluded from clinical trials.

67 Results From 109 included randomized clinical trials, 108 ASCOv1, 111 ASCOv2, and 83 ESMO sco

68 In this randomized clinical trial, 268 active-duty servicemembers consented

69 In a randomized clinical trial, 336 eligible participants who self-ident

70 In this phase IIb clinical trial, a 62% relative benefit from baseline was

71 s secondary analysis of a phase 3 randomized clinical trial, a low level of preexisting cytotoxic sTI

72 duced ejection fraction who were enrolled in clinical trials, a finding that is consistent with a cum

73 Although some of these vaccines are in clinical trials, a lack of knowledge about the molecular

74 -based therapies have been tested in phase I clinical trials, a quarter of which have reached phase I

75 tic options and the aggregation of data from clinical trials across different therapeutic approaches

76 ine the disorders and to empower appropriate clinical trials, along with improved genetic technologie

77 tions in sequential patient samples from the clinical trial and correlated these with clinical respon

78 e or had no financial coverage for ASCT in a clinical trial and instead received melphalan at 200 mg/

79 should be tested in a randomized controlled clinical trial and that the analysis should involve the

80 actions among nine Women's Health Initiative clinical trials and Atherosclerosis Risk in Communities

81 ndardized, objective assessments of itch for clinical trials and practice.

82 We included randomized clinical trials and prospective observational studies re

83 ion in patients with food allergy completing clinical trials and, in some studies, sustained unrespon

84 g 9 retrospective reports and one randomized clinical trial, and five retrospective studies were incl

85 questions, summarises the results of recent clinical trials, and gives an overview of ongoing studie

86 naive patients in the CLL8, CLL10, and CLL11 clinical trials, and quantified by 4-color flow cytometr

87 es for randomized controlled trials, ongoing clinical trials, and unpublished studies up to August 20

88 y using a frequentist approach (conventional clinical trial approach independent of prior data) from

89 Treg cells currently used in clinical trials are either polyclonal, donor- or antigen

90 Further clinical trials are indicated to improve anatomic and vi

91 Larger scale clinical trials are needed to assess the efficacy of gam

92 prove vascular diseases; however, randomized clinical trials are needed to confirm these findings.

93 Well-controlled multicenter clinical trials are ongoing and data are awaited.

94 ible, most drugs currently being assessed in clinical trials are targeting the downstream sequelae of

95 Clinical trials are underway with additional drugs.

96 cardiotoxicity, suggesting that prospective clinical trials are warranted to test this hypothesis.

97 This post hoc analysis of a clinical trial assessed the medical claims forms and rec

98 the pig provide a rational basis for future clinical trials assessing the benefits of this approach

99 gical interventions (eg, surgical randomized clinical trials) blinding is usually more difficult.

100 A phase 3 clinical trial (BMT CTN 0402) comparing tacrolimus/sirol

101 RSV entry blockers are in clinical trials, but escape mutations challenge their po

102 is parallel-design, double-blind, randomized clinical trial, called Resveratrol to Improve Outcomes i

103 be characterized and planned for now so that clinical trials can progress expediently and effectively

104 enetics were retrieved (reviews, guidelines, clinical trials, case series), and their bibliographies

105 ia, including hospitals, health centres, and clinical trial centres.

106 atelet Inhibition [PLATFORM]: NCT00385138; A Clinical Trial Comparing Cangrelor to Clopidogrel Standa

107 BENEFIT was a randomized clinical trial comparing early versus delayed interferon

108 dely used in place of amphotericin; however, clinical trials comparing these two treatments are lacki

109 Randomized clinical trial conducted at 2 urban EDs in the Bronx, Ne

110 estigator-blinded, 6-month, 2-arm randomized clinical trial conducted between January 22 and November

111 Randomized clinical trial conducted between October 2014 and May 20

112 a randomized, open-label, blinded end-point clinical trial conducted in 8 comprehensive stroke cente

113 a from animal studies and a ring vaccination clinical trial conducted in Guinea during the recent epi

114 ve results in preclinical experiments and in clinical trials conducted in radiosensitive malignancies

115 ll reassess these estimates in light of more clinical trial data and to understand the effect on an i

116 tion and summarizes the current registry and clinical trial data applicable to this frequently encoun

117 We used clinical trial data from three cohorts of clinical trial

118 n or associated publication of articles once clinical trial data have been widely shared.

119 of CAS versus CEA, given recently published clinical trial data.

120 This randomized clinical trial demonstrated better postoperative outcome

121 significant interest with the completion of clinical trials demonstrating efficacy.

122 The lack of prospective randomized clinical trials demonstrating that full-body skin examin

123 within the same platform structure and makes clinical trial design decisions more explicit.

124 timal assay for patient selection may inform clinical trial design for immunotherapy in pancreatic ca

125 Although clinical trial design is challenging, due in part to a l

126 physicochemical design principles, and (ii) clinical trial design, which are frequently overlooked i

127 cular importance to routine patient care and clinical trial design.

128 n-Small Cell Lung Cancer patients for use in clinical trial design.

129 , we anticipate ongoing in vivo research and clinical trial development of ASOs for the treatment of

130 Selected publications describing angioedema, clinical trials, diagnosis, management, and genetics wer

131 The broadening of clinical trial eligibility criteria can be considered to

132 Predictive biomarkers and novel clinical trial end points, such as volumetric measuremen

133 ngs opportunity-the more rapid completion of clinical trials, enhanced generalizability of the result

134 t B of these randomised, phase 2, open-label clinical trials enrolled individuals from 15 countries w

135 The trial was registered with the European Clinical Trials (EudraCT) database (no 2009-014907-29) a

136 D (NCT01500304) is a multicenter, phase I/II clinical trial evaluating the safety and feasibility of

137 quantifying Rab10-pThr73 levels in upcoming clinical trials evaluating LRRK2 kinase inhibition as a

138 omarkers to identify high-risk patients, and clinical trials evaluating novel therapies should be foc

139 breakthrough event is based on minimal or no clinical trial evidence.

140 While guidance on statistical principles for clinical trials exists, there is an absence of guidance

141 ment in 2-year control from 34% of our prior clinical trial experience with 63 to 69 Gy in a similar

142 ation Society convened a group of transplant clinical trial experts to address these problems.

143 Bryostatin is in clinical trials for Alzheimer's disease, cancer, and HIV

144 that the small molecule LGK974, which is in clinical trials for managing Wnt-driven tumors, is a bon

145 (AAV) vectors have been used successfully in clinical trials for patients with hemophilia or blindnes

146 tal of 84 patients who have been enrolled in clinical trials for Progeria at Boston Children's Hospit

147 ipsagargin, which is currently in late-stage clinical trials for the treatment of cancer, will also b

148 lysine demethylase 1 inhibitor currently in clinical trials for the treatment of small cell lung car

149 ars of preclinical work, including the first clinical trials for therapeutics and vaccines.

150 ans or animals, and there are no large-scale clinical trials for therapies against MERS-CoV.

151 ur data warrant the development of pediatric clinical trials for this particularly vulnerable patient

152 itial meta-analysis identified 14 randomized clinical trials for treatment of mNSCLC with active cont

153 f the HIV Prevention Trials Network and AIDS Clinical Trials Group.

154 However, a long history of failed clinical trials has demonstrated that broad-spectrum MMP

155 Several clinical trials have already demonstrated that combinati

156 cardiovascular medicine fueled by innovative clinical trials have dramatically improved the lives of

157 The successes and failures of biologics in clinical trials have facilitated our ability to better u

158 Clinical trials have investigated the effects of agents

159 However, clinical trials have produced inconsistent results.

160 ficacy have been extensively demonstrated in clinical trials; however, its performance in routine hea

161 currently undergoing testing in a phase III clinical trial in early PD.

162 Randomized 2 x 2 factorial clinical trial in neonates (>/=36 weeks' gestation) with

163 Percutaneous Coronary Intervention) trial, a clinical trial in which 2,604 patients with chronic angi

164 viduals (SWIFT-C) is an open-label, 2-cohort clinical trial in which the first cohort assessed for th

165 Our study underscores the need for long-term clinical trials in adolescents with at least 5 years of

166 Because (131)I-CLR1404 has entered clinical trials in adults, our data warrant the developm

167 MLN4924 is currently undergoing clinical trials in cancer patients, and our experiments

168 ge in licensing, we review the outcomes from clinical trials in children with persistent AA receiving

169 ensus Development Conference on Criteria for Clinical Trials in Chronic Graft-Versus-Host Disease.

170 nsensus Development Projects on Criteria for Clinical Trials in Chronic GVHD standardized the termino

171 ial using endpoints that are traditional for clinical trials in Crohn's disease, and identify factors

172 m the 10 clinical trials of the Alliance for Clinical Trials in Oncology.

173 immunosuppression withdrawal (ITN030ST) and Clinical Trials in Organ Transplantation (CTOT-03) studi

174 ugs-a finding consistent with the results of clinical trials in patients at high cardiovascular risk.

175 r resistance that could be rapidly tested in clinical trials in patients with BRAF(V600E) brain tumor

176 ar, a licensed drug, should now be tested in clinical trials in patients.

177 marizes the current status and challenges of clinical trials in the genomic era and proposes ways to

178 relevant for refining inclusion criteria of clinical trials in the settings of T1D.

179 Therapies currently in clinical trials in the transplant setting include kerati

180 or treating NASH and underscore the need for clinical trials in this area.

181 from the large cohort of as-yet unpublished clinical trials in this arena.

182 There are several clinical trials in which recently approved drugs with kn

183 Randomized clinical trials in which self-guided iCBT was compared w

184 rallel-group, placebo-controlled, randomized clinical trial included 117 patients with planned dental

185 and selected studies if they were randomized clinical trials, included adults hospitalized with acute

186 In this 2-group, parallel, randomized clinical trial, including a nonrandomized observational

187 abstinent outcomes as efficacy indicators in clinical trials, including reduction in WHO drinking ris

188 good manufacturing practices manufacture and clinical trials intended to test the clinical effectiven

189 Clinical Review, an overview of the landmark clinical trials investigating checkpoint blockade in lun

190 inic keratosis in a randomized, double-blind clinical trial involving 131 participants.

191 A phase 1 clinical trial is in progress to investigate the therape

192 therapies, an earlier end point to expedite clinical trials is needed.

193 This study was a randomized clinical trial (Lutein Influence on Macula of Persons Is

194 SCHOLAR-1 pooled data from 2 phase 3 clinical trials (Lymphoma Academic Research Organization

195 Four randomized clinical trials met the selection criteria and included

196 Clinical trial no: EudraCT 2013-000730-36.

197 eviously enrolled in the HMII (HeartMate II) clinical trials, none of whom received octreotide, to pr

198 Concern, multiple vaccine candidates entered clinical trials, now totaling 7 products with an additio

199 A single arm phase 2 clinical trial of 15 patients with breast cancer previou

200 sibility of conducting an adequately powered clinical trial of DAA use for PEP and the low cost-effec

201 especified subgroup analysis of a randomized clinical trial of endovascular treatment for acute ische

202 alysis of secondary outcomes of a randomized clinical trial of extremely preterm infants, early low-d

203 Four-group cluster randomized clinical trial of mothers of healthy term newborns who w

204 In this 2-year, follow-up, randomized clinical trial of patients with Duchenne or Becker muscu

205 In a prospective clinical trial of patients with HCV-CV, DAA-based therap

206 nsulin should further be studied in a larger clinical trial of smoking cessation.

207 rdiovascular disease archived from a phase 3 clinical trial of tofacitinib and etanercept in adults w

208 ved efficacy profile would support a further clinical trial of XEN-D0501 in refractory chronic cough.

209 A post hoc analysis of clinical trials of adults with active (VISUAL-1) and ina

210 Included were randomized clinical trials of adults with diagnosed BPD randomized

211 Larger and longer phase II clinical trials of anastrozole may be warranted in patie

212 PB-MRD as a primary end point in randomized clinical trials of chemoimmunotherapy in CLL.

213 considered for the evaluation and design of clinical trials of curcumin and other polyphenols of med

214 of Parkinson's disease, which may be used in clinical trials of disease-modifying therapies.

215 from 3016 patients from 4 phase 3 randomized clinical trials of evolocumab as part of the Program to

216 Using published data from two clinical trials of immune checkpoint blockade therapy fo

217 with IBD, including two cohorts from phase 3 clinical trials of infliximab and golimumab, high pretre

218 nd rationale for management of the axilla in clinical trials of omission of cancer surgery when image

219 anslocations in two prospectively randomized clinical trials of patients with diffuse large B-cell ly

220 Clinical trials of secondary prevention treatment in MIN

221 These data are consistent with data from clinical trials of Selumetinib, suggesting that acute tr

222 itavastatin and diet should be controlled in clinical trials of statins.

223 Pragmatic clinical trials of terlipressin with albumin are warrant

224 Results (SEER) database and data from the 10 clinical trials of the Alliance for Clinical Trials in O

225 event congenital ZIKV disease and conducting clinical trials of these treatments, with a focus on pre

226 In this Review, we detail the ongoing clinical trials of Treg therapy in liver and kidney tran

227 Sensitive outcome measures for clinical trials on cerebellar ataxias are lacking.

228 Among the phase III clinical trials only the RV144 vaccine trial elicited si

229 sponsored, multicenter, phase 3, randomized clinical trial open to patients with biopsy-proven carci

230 ed clinical trial data from three cohorts of clinical trial participants in the LITRA, EMPOWER and PR

231 t the real-world patient population, improve clinical trial participation, and increase patient acces

232 In a pooled analysis of three phase III IPF clinical trials, patients receiving pirfenidone had a lo

233 ystematic reviews, meta-analyses, randomized clinical trials, prospective comparative observational s

234 Purpose Biomarker-based clinical trials provide efficiencies during therapeutic

235 English-language randomized clinical trials (RCTs) or prospective cohort studies tha

236 Clinical trial registered with www.isrctn.com (ISRCTN 69

237 Clinical trial registration no.

238 Clinical Trial Registration no: DRKS00003555.

239 Dutch Clinical Trial Registration no: NL30551.068.09.

240 out and completed before the requirement for clinical trial registration.

241 Clinical Trial Registration: NCT01306669.

242 In addition, there is a lack of clinical trials required to refine and update standardiz

243 ochrane database, TCTMD, ClinicalTrials.gov, Clinical Trial Results, CardioSource, and abstracts and

244 Double-masked, randomized noninferiority clinical trials: Rho Kinase Elevated IOP Treatment Trial

245 And, as the number of clinical trials rise each year, it is apparent that FGS

246 iciently long observation period outside the clinical trial scenario.

247 nation and should never be done outside of a clinical trial setting.

248 tive, open-label, non-inferiority randomised clinical trial (Sita-Hospital) in five hospitals in the

249 arly as the therapy is introduced beyond the clinical trial sites into general clinical practice.

250 tical to include elderly asthmatics in large clinical trials so that therapy may be better tailored t

251 thers have entered or will enter prospective clinical trials soon in several countries.

252 odegenerative diseases are expected to reach clinical trials soon.

253 Participants and clinical trial staff were not masked to treatment alloca

254 ral STAT3 inhibitors are currently tested in clinical trials, STAT3 might be a candidate for molecula

255 In this substudy of a randomized clinical trial, study eyes of subjects assigned to aceta

256 ile elderly patients are underrepresented in clinical trials, subgroup analysis of large clinical tri

257 Clinical trials, such as the ESETT (Established Status E

258 clinical trials, subgroup analysis of large clinical trials suggests they may be less likely to resp

259 Although some clinical trials targeting immune checkpoints have shown

260 ative science metrics emerge for an upcoming clinical trial, testing enhancement of immune checkpoint

261 analysis of the multicenter FinXX randomized clinical trial that accrued 1500 women in Finland and Sw

262 We demonstrated in a randomized clinical trial that vitamin C supplementation to pregnan

263 g exploited to treat patients with dozens of clinical trials that aim to manipulate autophagy to trea

264 consent process, if any, should be used for clinical trials that compare two or more interventions w

265 ques used in major observational studies and clinical trials that form the evidence base for our curr

266 Clinical trials that include racial and ethnic groups ne

267 eater than perhaps the strongest adjuvant in clinical trials (that is, CpG in Montanide).

268 A multicenter phase 2 randomized clinical trial, the Arginine Deiminase and Mesothelioma

269 onse rates are around 20% in the majority of clinical trials, there is much room for improvement.

270 In a large clinical trial, this new drug was found to reduce hospit

271 (A Clinical Trial to Demonstrate the Efficacy of Cangrelor

272 Purpose To conduct a pilot prospective clinical trial to evaluate the feasibility, safety, and

273 -analysis and create a network of randomized clinical trials to compare outcomes after specific treat

274 ies support the inflammatory hypothesis, but clinical trials to confirm the therapeutic potential to

275 Two clinical trials to define novel ways of using an existin

276 geted treatments, and strategies to optimize clinical trials to efficiently and effectively test thes

277 are conflicting, and there are no randomized clinical trials to guide practitioner decision making.

278 r race-adapted cancer screening programs and clinical trials to reduce disparities in cancer burden.

279 sian analysis takes evidence from randomized clinical trials to update what is already known about sp

280 With few Schistosoma vaccine candidates in clinical trials, unexplored antigens from the vulnerable

281 omisation was achieved using the Southampton Clinical Trials Unit telephone randomisation service by

282 , single-blind, placebo-controlled crossover clinical trial was conducted from December 19, 2011, thr

283 A randomized clinical trial was conducted from February 1 to August 3

284 ouble-blinded, placebo-controlled randomized clinical trial was conducted from October 1, 2013, throu

285 type 2 diabetes (T2D).A randomized crossover clinical trial was conducted in patients with T2D.

286 ing 1 to healthy human volunteers, a phase I clinical trial was conducted.

287 The objective of this prospective clinical trial was to assess the influence of the type o

288 double-blind, placebo-controlled, randomized clinical trial, was conducted from March 1, 2010, to Sep

289 studies, retrospective clinical studies, and clinical trials, we examined the biology of AR and AR-re

290 vidual participant data from GlaxoSmithKline clinical trials were obtained through Clinical Study Dat

291 e preclinical transplant models and in human clinical trials while maintaining a robust graft-versus-

292 is hoped that data from ongoing and planned clinical trials will allow us to routinely add targeted

293 A clinical trial with 6 APDS patients was conducted as a 1

294 reast cancer subtypes in a large, randomized clinical trial with long-term follow-up.

295 hus be assessed for response and included in clinical trials with appropriate stratification.

296 However, phase I and II clinical trials with autologous and first-generation ste

297 ied 1536 samples obtained from 3 independent clinical trials with drisapersen, an antisense oligonucl

298 ractory multiple myeloma who were treated in clinical trials with IMiD-containing regimens.

299 More recently, clinical trials with Janus kinase (JAK) inhibitors have

300 ative imaging package optimized for oncology clinical trial workflows.